Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia
Background: Programmed Death Ligand 1 (PD-L1) expression was used to determine type of patients who respond to immunotherapy using immune checkpoint inhibitor in several solid malignancies. However, the role of PD-L1 in hematological malignancies is less explored. Therefore, we aim to investigate PD...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
West Asia Organization for Cancer Prevention
2021-03-01
|
| Series: | Asian Pacific Journal of Cancer Biology |
| Subjects: | |
| Online Access: | http://www.waocp.com/journal/index.php/apjcb/article/view/627 |
| _version_ | 1797341130563518464 |
|---|---|
| author | Muhammad Al Azhar Chainurridha . Mururul Aisyi |
| author_facet | Muhammad Al Azhar Chainurridha . Mururul Aisyi |
| author_sort | Muhammad Al Azhar |
| collection | DOAJ |
| description | Background: Programmed Death Ligand 1 (PD-L1) expression was used to determine type of patients who respond to immunotherapy using immune checkpoint inhibitor in several solid malignancies. However, the role of PD-L1 in hematological malignancies is less explored. Therefore, we aim to investigate PD-L1 mRNA expression in childhood leukemia patients. Association between PD-L1 expression and clinicopathological features was also analyzed.
Method: Blood samples of 17 childhood leukemia patients and 12 healthy individuals as control were used in this study. The samples were collected in Dharmais Cancer Hospital. Real time PCR was used to analyze PD-L1 expression with GAPDH as internal control.
Result: PD-L1 mRNA expression is significantly lower in childhood leukemia patients (medians: 0.0012) compared to healthy individuals (medians: 0.0041) (p=0.017). PD-L1 mRNA expressions were not correlated with age (p=1.000), sex (p=1.000), outcome (p=1.000), type of leukemia (p=1.000), hyperleukocytosis (p=1.000), and syndrome down (p=0.426).
Conclusion: PD-L1 expression is lower in leukemia patients compared to healthy controls. PD-L1 expressions were not correlated with all clinicopathological features. Our result provides preliminary data of PD-L1 expression in Indonesian childhood leukemia patients. |
| first_indexed | 2024-03-08T10:14:12Z |
| format | Article |
| id | doaj.art-fd20f18d872744e78bac9bddc15cf7c6 |
| institution | Directory Open Access Journal |
| issn | 2538-4635 |
| language | English |
| last_indexed | 2024-03-08T10:14:12Z |
| publishDate | 2021-03-01 |
| publisher | West Asia Organization for Cancer Prevention |
| record_format | Article |
| series | Asian Pacific Journal of Cancer Biology |
| spelling | doaj.art-fd20f18d872744e78bac9bddc15cf7c62024-01-29T06:30:03ZengWest Asia Organization for Cancer PreventionAsian Pacific Journal of Cancer Biology2538-46352021-03-0161374110.31557/apjcb.2021.6.1.37-41627Profile of PD-L1 mRNA Expression in Childhood Acute LeukemiaMuhammad Al Azhar0Chainurridha .1Mururul Aisyi21Research and Development Department, National Cancer Center-Dharmais Cancer Hospital, Jakarta1 Research and Development Department, National Cancer Center-Dharmais Cancer Hospital, Jakarta, Indonesia1 Research and Development Department, National Cancer Center-Dharmais Cancer Hospital, Jakarta, Indonesia. Department of Paediatric Oncology, National Cancer Center-Dharmais Cancer Hospital, Jakarta, IndonesiaBackground: Programmed Death Ligand 1 (PD-L1) expression was used to determine type of patients who respond to immunotherapy using immune checkpoint inhibitor in several solid malignancies. However, the role of PD-L1 in hematological malignancies is less explored. Therefore, we aim to investigate PD-L1 mRNA expression in childhood leukemia patients. Association between PD-L1 expression and clinicopathological features was also analyzed. Method: Blood samples of 17 childhood leukemia patients and 12 healthy individuals as control were used in this study. The samples were collected in Dharmais Cancer Hospital. Real time PCR was used to analyze PD-L1 expression with GAPDH as internal control. Result: PD-L1 mRNA expression is significantly lower in childhood leukemia patients (medians: 0.0012) compared to healthy individuals (medians: 0.0041) (p=0.017). PD-L1 mRNA expressions were not correlated with age (p=1.000), sex (p=1.000), outcome (p=1.000), type of leukemia (p=1.000), hyperleukocytosis (p=1.000), and syndrome down (p=0.426). Conclusion: PD-L1 expression is lower in leukemia patients compared to healthy controls. PD-L1 expressions were not correlated with all clinicopathological features. Our result provides preliminary data of PD-L1 expression in Indonesian childhood leukemia patients.http://www.waocp.com/journal/index.php/apjcb/article/view/627childhood acute leukemia, pd-l1, immunotherapy, immune checkpoint inhibitor |
| spellingShingle | Muhammad Al Azhar Chainurridha . Mururul Aisyi Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia Asian Pacific Journal of Cancer Biology childhood acute leukemia, pd-l1, immunotherapy, immune checkpoint inhibitor |
| title | Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia |
| title_full | Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia |
| title_fullStr | Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia |
| title_full_unstemmed | Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia |
| title_short | Profile of PD-L1 mRNA Expression in Childhood Acute Leukemia |
| title_sort | profile of pd l1 mrna expression in childhood acute leukemia |
| topic | childhood acute leukemia, pd-l1, immunotherapy, immune checkpoint inhibitor |
| url | http://www.waocp.com/journal/index.php/apjcb/article/view/627 |
| work_keys_str_mv | AT muhammadalazhar profileofpdl1mrnaexpressioninchildhoodacuteleukemia AT chainurridha profileofpdl1mrnaexpressioninchildhoodacuteleukemia AT mururulaisyi profileofpdl1mrnaexpressioninchildhoodacuteleukemia |